tirzepatide trial Effect of in SURMOUNT-1 trial. (BMI: body mass index; CI: Overview of the SURPASS phase

Description

Introduction Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are key therapies for type 2 diabetes and obesity, regulating blood glucose by mimicking endogenous GLP-1

Promueve la sensacin de saciedad ms rpida, ayudando al control del peso

95% CI 0.89, 0.96) and all-cause mortality rate (HR 0.70

The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme demonstrated that adults using semaglutide 2.4 mg weekly alongside lifestyle intervention lost an average of approximately 15% of their body weight over 68 weeks, compared to around 2.4% with placebo. NICE approved Wegovy for use in specialist weight management services in the UK in 2023 (TA875), recognising its clinical effectiveness. Ongoing research continues to explore its cardiovascular benefits, with the SELECT trial showing a significant reduction in major cardiovascular events in people with obesity